These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 7471099

  • 21. DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum(II) and L-phenylalanine mustard.
    Zwelling LA, Michaels S, Schwartz H, Dobson PP, Kohn KW.
    Cancer Res; 1981 Feb; 41(2):640-9. PubMed ID: 7192601
    [No Abstract] [Full Text] [Related]

  • 22. Preclinical antitumor activity of bizelesin in mice.
    Carter CA, Waud WR, Li LH, DeKoning TF, McGovren JP, Plowman J.
    Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280
    [Abstract] [Full Text] [Related]

  • 23. Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. III. Control of host resistance to drug-resistant L1210 sublines by H-2-linked and non-H-2-linked genes.
    Fuji H, Murakami M.
    J Natl Cancer Inst; 1983 Jan; 70(1):119-25. PubMed ID: 6296515
    [Abstract] [Full Text] [Related]

  • 24. [A method of primary selection of antitumor agents].
    Karaivanova MKh.
    Vopr Onkol; 1971 Jan; 17(2):62-6. PubMed ID: 5567711
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Kethoxal bis(thiosemicarbazone). I. Effects against experimental tumors.
    Mihich E, Nichol CA.
    Cancer Res; 1965 Oct; 25(9):1410-6. PubMed ID: 5217028
    [No Abstract] [Full Text] [Related]

  • 30. Mechanism of actinomycin D-induced resistance in Ridgway osteogenic sarcoma: an ultrastructural study.
    Kamel HM, Merry S, Toner PG.
    J Submicrosc Cytol Pathol; 1988 Jan; 20(1):225-35. PubMed ID: 3163515
    [Abstract] [Full Text] [Related]

  • 31. The role of hyperthermia in regional alkylating agent chemotherapy.
    Abdel-Wahab OI, Grubbs E, Viglianti BL, Cheng TY, Ueno T, Ko S, Rabbani Z, Curtis S, Pruitt SK, Dewhirst MW, Tyler DS.
    Clin Cancer Res; 2004 Sep 01; 10(17):5919-29. PubMed ID: 15355925
    [Abstract] [Full Text] [Related]

  • 32. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.
    Gorelik L, Rubin M, Prokhorova A, Mokyr MB.
    J Immunol; 1995 Apr 15; 154(8):3941-51. PubMed ID: 7706732
    [Abstract] [Full Text] [Related]

  • 33. Time dependence of [3H]-vincristine accumulation by L1210 mouse leukemic cells. Effect of P-glycoprotein overexpression.
    Breier A, Stefanková Z, Barancík M, Tribulová N.
    Gen Physiol Biophys; 1994 Aug 15; 13(4):287-98. PubMed ID: 7890145
    [Abstract] [Full Text] [Related]

  • 34. Quantification and morphologic demonstration of reactive oxygen species produced by Walker 256 tumor cells in vitro and during metastasis in vivo.
    Soares FA, Shaughnessy SG, MacLarkey WR, Orr FW.
    Lab Invest; 1994 Oct 15; 71(4):480-9. PubMed ID: 7967504
    [Abstract] [Full Text] [Related]

  • 35. Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.
    Harrison SD, Plowman J, Dykes DJ, Waud WR, Griswold DP.
    Cancer Chemother Pharmacol; 1990 Oct 15; 25(6):425-9. PubMed ID: 2311170
    [Abstract] [Full Text] [Related]

  • 36. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP, Reynolds CP.
    Bone Marrow Transplant; 2002 Aug 15; 30(3):135-40. PubMed ID: 12189530
    [Abstract] [Full Text] [Related]

  • 37. Prostate carcinoma response to cytotoxic therapy: in vivo resistance.
    Teicher BA, Kakeji Y, Ara G, Herbst RS, Northey D.
    In Vivo; 1997 Aug 15; 11(6):453-61. PubMed ID: 9509295
    [Abstract] [Full Text] [Related]

  • 38. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
    Jounaidi Y, Waxman DJ.
    Cancer Res; 2001 Jun 01; 61(11):4437-44. PubMed ID: 11389073
    [Abstract] [Full Text] [Related]

  • 39. Investigation on cyclophosphamide treatment during the preimplantation period. II. In vitro studies on the effects of cyclophosphamide and its metabolites 4-OH-cyclophosphamide, phosphoramide mustard, and acrolein on blastulation of four-cell and eight-cell mouse embryos and on their subsequent development during implantation.
    Spielmann H, Jacob-Müller U.
    Teratology; 1981 Feb 01; 23(1):7-13. PubMed ID: 7245091
    [Abstract] [Full Text] [Related]

  • 40. [Characteristics of growth and sensitivity to cytostatics of Walker 256 carcinosarcoma in randombred and Wistar rats].
    Karaivanova MK.
    Eksp Med Morfol; 1974 Feb 01; 13(4):237-42. PubMed ID: 4219353
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.